Praveen Vikas MD, FASCO

Oncologist, Breast cancer researcher, Associate Professor, University of Iowa Comprehensive Cancer Center, Community-academic partnership in cancer Care.

[Praveen Vikas MD, FASCO @killthecancer]

@cancermd @AstraZeneca Congratulations Sunil.

[Praveen Vikas MD, FASCO @killthecancer]

As expected, we now have data showing T-DXd benefit in Her 2-low (IHC 1+ or 2+/ISH-) and ultra-low( IHC 0 with membrane staining; IHC >0<1+ ) ER positive metastatic breast cancer, that are chemo-naive. PFS benefit per AZ press release, OS not mature.
https://t.co/EPDpteg23o!

[Nicole Grogan Fleege, MD @NicoleFleege]

Join us 5/15 for a night all about discussing updates in the tx of breast cancer! Myself & my three breast med onc colleagues from @uihealthcare @UIowaCancer will be there. Excited to update everyone on the state of breast cancer care!

Register here: https://t.co/hGsNGNzsPl

[Praveen Vikas MD, FASCO @killthecancer]

This is a remarkable moment in Medicine!! First approved therapy baesd on CRISPR gene editing technology!!

FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease https://t.co/7JGigaxazW

[Praveen Vikas MD, FASCO @killthecancer]

Felt wonderful catching up with colleagues and collaborators at the most influential Breast cancer conference!!

[Praveen Vikas MD, FASCO @killthecancer]

Another exciting treatment option for ER positive advanced breast cancer patient!

[Praveen Vikas MD, FASCO @killthecancer]

@DrDawnHershman @ColumbiaMed @columbiacancer Congratulations!! Very well deserved !!

[Praveen Vikas MD, FASCO @killthecancer]

Another ADC, Exciting results !
Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial https://t.co/5t4LtI9zph

[Praveen Vikas MD, FASCO @killthecancer]

@pashtoonkasi Congratulations!! Amazing work!!

[Praveen Vikas MD, FASCO @killthecancer]

Deeply honored to receive the FASCO distinction. Congratulations to all the distinguished ASCO members. So grateful @ASCO.

[ASCO @ASCO]

🎉 Join us in congratulating the following members on earning the Fellow of ASCO (FASCO) distinction this quarter! We're grateful for their extraordinary volunteer service, dedication, and commitment to ASCO. Learn more about the FASCO distinction: https://t.co/FPX6Umt60A

[Praveen Vikas MD, FASCO @killthecancer]

Looking forward to this educational event next week !!

[OncLive.com @OncLive]

Registration is open! Join Praveen Vikas, MD, FACP, FASCO of @UIowaCancer as he chairs an OncLive SOSS Breast Cancer in-person education and networking event on 9/7 at 6:00 PM! #SOSS @killthecancer

Register Today: https://t.co/UXN44ATxO9

[Praveen Vikas MD, FASCO @killthecancer]

@HarneetWalia1 @BrainTumorDoc @AAPIUSA @MiamiCancerInst @BaptistHealthSF @ASCO @NeuroOnc congratulations ! Very well deserved.

[Praveen Vikas MD, FASCO @killthecancer]

@MattGubensMD @UCSF @UCSFCancer Congratulations @MattGubensMD !!

[Praveen Vikas MD, FASCO @killthecancer]

@umangtalking @neerajaiims @huntsmancancer @NeliMUlrich @UUtah @ggebraelmd @nsayeghmd @TripNish @bev_chigarira @vinay_onc @GliceidaGalarza @TomVargheseJr @montypal @PGrivasMDPhD @ZakhariaYousef @Huntsman_GU congratulations @umangtalking !!

[Praveen Vikas MD, FASCO @killthecancer]

@dr_yakupergun @pehengui I agree!! If access is not an issue, I would continue Pembro in adjuvant setting along with 6-8 cycles of capecitabine and RT if needed, followed by Olaparib for high risk TNBC with residual disease!

[Yakup Ergün @dr_yakupergun]

ASCO Educational Book

Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between

@ASCO @OncoAlert

https://t.co/eLH6Q76CYQ

[Praveen Vikas MD, FASCO @killthecancer]

Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between https://t.co/yC3vHMyORC